• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Ray Sumita

    10/11/23 9:40:00 PM ET
    $VAXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VAXX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Ray Sumita

    (Last) (First) (Middle)
    505 ODYSSEY WAY

    (Street)
    MERRITT ISLAND FL 32953

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/01/2023
    3. Issuer Name and Ticker or Trading Symbol
    Vaxxinity, Inc. [ VAXX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Legal Officer, Secretary
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Sumita Ray 10/11/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VAXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAXX

    DatePrice TargetRatingAnalyst
    9/8/2023$7.00Outperform
    Robert W. Baird
    4/27/2022In-line
    Evercore ISI
    12/29/2021$18.00Buy
    Jefferies
    12/7/2021$18.00Buy
    Jefferies
    12/6/2021$21.00Buy
    B of A Securities
    More analyst ratings

    $VAXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine

      UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC:VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy medicines), announced today that Nature Medicine has published groundbreaking exploratory data from the Company's Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD). The succes

      6/20/24 6:00:00 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Issues Shareholder Letter

      CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longer be publicly traded on the NASDAQ exchange. It is important to share why we made this decision to "go dark" and why we believe it is in the best interests of the company and our shareholders over

      4/19/24 6:53:35 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

      CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market ("Nasdaq") and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. On February 9, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the Company was no longer

      4/19/24 4:27:16 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vaxxinity Inc. (Amendment)

      SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)

      2/12/24 5:02:01 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vaxxinity Inc. (Amendment)

      SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)

      2/12/24 5:02:04 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Vaxxinity Inc. (Amendment)

      SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)

      2/7/24 4:35:42 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

      Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity's leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity's board of directors. Peter will oversee the overall scientific direction of Vaxxinity's platform and programs, and lead the development efforts at Vaxxinity. "Get ready for the next wave of innovative drug science at V

      7/27/23 4:30:36 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida

      Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories ("VaxxLabs") in Cape Canaveral, Fla., as corporate headquarters CAPE CANAVERAL, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla. "Today's announcements reflect the strength of Vaxxinity's science and people and further equip us to achieve key research and commercial milestones as we prepare to launch our fir

      2/1/23 7:40:51 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

      DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity's Executive Vice President, Research & Development. This transition will be effective March 31, 2022 and will increase the size of the Board to seven. "Peter is a rockstar of drug development who has contributed to the approval of over half a dozen new drugs that help patients to this day. We are fortunate to have him joining our Board where we may continue to leverage his considerable expertise to dev

      3/21/22 7:00:00 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Vaxxinity with a new price target

      Robert W. Baird initiated coverage of Vaxxinity with a rating of Outperform and set a new price target of $7.00

      9/8/23 7:38:37 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Vaxxinity

      Evercore ISI initiated coverage of Vaxxinity with a rating of In-line

      4/27/22 9:03:26 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Vaxxinity with a new price target

      Jefferies resumed coverage of Vaxxinity with a rating of Buy and set a new price target of $18.00

      12/29/21 7:23:06 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Ray Sumita

      4 - Vaxxinity, Inc. (0001851657) (Issuer)

      4/29/24 4:15:15 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Paula Molina Rene

      4 - Vaxxinity, Inc. (0001851657) (Issuer)

      11/3/23 4:31:37 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Powchik Peter

      4 - Vaxxinity, Inc. (0001851657) (Issuer)

      10/11/23 9:42:02 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VAXX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vaxxinity Inc.

      15-12G - Vaxxinity, Inc. (0001851657) (Filer)

      5/9/24 4:24:53 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14C filed by Vaxxinity Inc.

      DEF 14C - Vaxxinity, Inc. (0001851657) (Filer)

      5/9/24 4:09:43 PM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Vaxxinity Inc.

      EFFECT - Vaxxinity, Inc. (0001851657) (Filer)

      5/3/24 12:15:22 AM ET
      $VAXX
      Biotechnology: Pharmaceutical Preparations
      Health Care